Genesis Protect availability
Use this page to understand current Genesis Protect Acute availability before evaluating a trip, cohort, integration, or review.
Genesis Protect Acute has limited, reserve-gated launch availability and is not broadly available insurance today.
What is true now
Travel 30is the primary Founder launch SKU.Event 7is the short-window event SKU.- Product terms, evidence requirements, and reserve-lane wording are published.
- Phase 0 claim review is staffed and supported by AI.
- Protection issuance depends on posted reserve, staffed review operations, and published product configuration staying consistent.
- Travel 30 Founder access uses a $99 reservation reference for the first 100-seat cohort. The target cap is reserve-indexed up to $250,000 and requires posted claims-paying reserve, sponsor, LP, or backstop support before activation. Exact cap and terms lock before active cover starts.
- The website devnet simulator can show a $200,000 Travel 30 demo cap from a simulated reserve/backstop snapshot. That is QA state only; it is not mainnet cover, not a real payout obligation, and not a change to the public $250,000 Founder target.
Current limits
- Genesis Protect Acute is not broad always-on public insurance today.
- Claim review is not fully decentralized today.
- App membership fees are separate from claims-paying reserve.
- Unposted demand, expected yield, or buyer interest does not count as reserve.
- Availability depends on reserve, staffing, schema, pricing, and benefits staying aligned with published terms.
Issuance gates
| Gate | Travel 30 | Event 7 |
|---|---|---|
| Posted reserve | Travel 30 premium, liquidity, sponsor, or backstop lanes must support the cap shown at activation. Pending reservations do not count as claims-paying reserve. | Event 7 premium, sponsor, or liquidity support must cover the approved cohort or issuance window. |
| Review staffing | Staffed claim review must be available for the active issuance window. | Staffed claim review must be available for the active issuance window. |
| Public terms | Published pricing, benefits, exclusions, and evidence requirements must stay aligned. | Published pricing, benefits, exclusions, sponsor terms, and evidence requirements must stay aligned. |
| Product configuration | Shared public evidence schema and product configuration must remain consistent. | Shared public evidence schema and product configuration must remain consistent. |
| Concentration | The first Travel 30 Founder cohort is capped at 100 seats; larger cohorts need sponsor or backstop review before issuance. | Event 7 cohorts stay capped by named venue or event preparation. |
Published product terms, accepted purchase or cohort terms, and issued window documents govern the active benefit. These docs explain the public model and do not replace the governing terms for a specific window.
When availability can change
Availability can pause or narrow when:
- posted reserve no longer covers the marketed issuance window
- claim-review or oracle staffing falls below the Phase 0 review requirement
- published schema, pricing, benefits, or evidence requirements drift from product configuration
- sponsor-backed issuance lacks explicit sponsor or backstop support
- public product language would imply broad insurance availability instead of bounded launch availability
Reader checklist
| Reader | Check before proceeding |
|---|---|
| Member | The protection window is active, the SKU fits the event, and the evidence expectations are clear. |
| Sponsor | The cohort lane, reserve source, review staffing, and published terms are explicit. |
| Builder | Use the public SDK docs for supported builder flows; product availability is governed by published availability gates. |
| Product operator | Product availability, reserve state, and staffing are aligned before availability stays open. |